KR20180085062A - 피부 상태를 치료하기 위한 조성물 및 방법 - Google Patents

피부 상태를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number: KR20180085062A
Authority: KR; South Korea
Prior art keywords: composition; skin conditions; treating skin; treating; conditions
Prior art date: 2010-11-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

KR1020187020451A

Other languages

English (en)

Other versions

KR101962658B1 (ko

Inventor

마크 제이 잭슨

Original Assignee

442 벤쳐스 엘엘씨

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-04

Filing date

2011-11-03

Publication date

2018-07-25

2011-11-03 Application filed by 442 벤쳐스 엘엘씨 filed Critical 442 벤쳐스 엘엘씨

2018-07-25 Publication of KR20180085062A publication Critical patent/KR20180085062A/ko

2019-07-31 Application granted granted Critical

2019-07-31 Publication of KR101962658B1 publication Critical patent/KR101962658B1/ko

Status Active legal-status Critical Current

2031-11-03 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1020187020451A 2010-11-04 2011-11-03 피부 상태를 치료하기 위한 조성물 및 방법 Active KR101962658B1 (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41011010P	2010-11-04	2010-11-04
US61/410,110		2010-11-04
PCT/US2011/059206 WO2012061630A2 (en)	2010-11-04	2011-11-03	Composition and method for treating skin conditions

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020137014213A Division KR20130100346A (ko)	2010-11-04	2011-11-03	피부 상태를 치료하기 위한 조성물 및 방법

Publications (2)

Publication Number	Publication Date
KR20180085062A true KR20180085062A (ko)	2018-07-25
KR101962658B1 KR101962658B1 (ko)	2019-07-31

Family

ID=46020220

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
KR1020137014213A Ceased KR20130100346A (ko)	2010-11-04	2011-11-03	피부 상태를 치료하기 위한 조성물 및 방법
KR1020187020451A Active KR101962658B1 (ko)	2010-11-04	2011-11-03	피부 상태를 치료하기 위한 조성물 및 방법

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
KR1020137014213A Ceased KR20130100346A (ko)	2010-11-04	2011-11-03	피부 상태를 치료하기 위한 조성물 및 방법

Country Status (13)

Country	Link
US (5)	US20120115821A1 (ko)
EP (1)	EP2635276B1 (ko)
JP (3)	JP2013541590A (ko)
KR (2)	KR20130100346A (ko)
CN (2)	CN103269702A (ko)
AU (1)	AU2011323271B2 (ko)
BR (1)	BR112013011156B1 (ko)
CA (1)	CA2816872C (ko)
MX (1)	MX339198B (ko)
NZ (1)	NZ610136A (ko)
RU (1)	RU2578979C2 (ko)
WO (1)	WO2012061630A2 (ko)
ZA (1)	ZA201303222B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX339198B (es) *	2010-11-04	2016-05-16	442 Ventures Llc	Composicion y metodo para tratar condiciones de la piel.
RS60672B1 (sr) *	2015-06-18	2020-09-30	Bausch Health Ireland Ltd	Topikalne kompozicije koje sadrže kortikosteroide i retinoid za lečenje psorijaze
US20190133943A1 (en) *	2015-06-18	2019-05-09	Valeant Pharmaceuticals North America	Topical compositions and methods for treating skin diseases
FR3051673B1 (fr) *	2016-05-24	2018-06-22	Assistance Publique - Hopitaux De Paris	Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
US11311482B2 (en)	2017-05-12	2022-04-26	Bausch Health Us, Llc	Topical compositions and methods for treating skin diseases
WO2019126744A1 (en) *	2017-12-21	2019-06-27	The Angiogenesis Foundation	Compositions and methods for treating neoplasia
WO2020010108A1 (en) *	2018-07-05	2020-01-09	The General Hospital Corporation	Compositions and methods for local delivery of pharmaceutical agents to treat cancer
AR122420A1 (es)	2020-04-16	2022-09-07	Baek Clinical Inc	Formulaciones tópicas no acuosas
CA3177393A1 (en)	2020-04-16	2021-10-21	Baek Clinical Inc.	High-potency vitamin c and sugar alcohol topical formulations
WO2023069639A1 (en) *	2021-10-20	2023-04-27	Baek Clinical Inc.	Anhydrous urea emulsions with a retinoid agent
ES2940736B2 (es) *	2021-11-09	2023-09-19	Ntd Labs S L U	Uso combinado de imiquimod y de un hidrolizado de caseina para el tratamiento de condilomas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2174533T3 (es) *	1997-11-25	2002-11-01	Yamanouchi Europ Bv	Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
US7276506B2 (en) *	1998-12-28	2007-10-02	4 Aza Bioscience Nv	Immunosuppressive effects of pteridine derivatives
US20030072814A1 (en) *	1999-12-16	2003-04-17	Maibach Howard I.	Topical pharmaceutical composition for the treatment of warts
US20010049546A1 (en) *	2000-02-08	2001-12-06	Israel Dvoretzky	Multi-purpose drug and heat therapy treatment system
US20090232755A1 (en) *	2003-07-28	2009-09-17	Leslie Baumann	Combination therapies for treating photodamaged skin
US8940755B2 (en) *	2003-12-02	2015-01-27	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
WO2008010963A2 (en)	2006-07-18	2008-01-24	3M Innovative Properties Company	Immune response modifier formulations
EP1958613A1 (en) *	2007-02-15	2008-08-20	Polichem S.A.	Dermal film-forming liquid formulations for drug release to skin
US8518376B2 (en) *	2007-12-07	2013-08-27	Foamix Ltd.	Oil-based foamable carriers and formulations
US20090182004A1 (en) *	2008-01-15	2009-07-16	Gareth Winckle	Imiquimod formulation
MX339198B (es) *	2010-11-04	2016-05-16	442 Ventures Llc	Composicion y metodo para tratar condiciones de la piel.

2011
- 2011-11-03 MX MX2013005078A patent/MX339198B/es active IP Right Grant
- 2011-11-03 NZ NZ610136A patent/NZ610136A/en not_active IP Right Cessation
- 2011-11-03 AU AU2011323271A patent/AU2011323271B2/en not_active Ceased
- 2011-11-03 RU RU2013126371/15A patent/RU2578979C2/ru active
- 2011-11-03 CA CA2816872A patent/CA2816872C/en active Active
- 2011-11-03 EP EP11838830.5A patent/EP2635276B1/en active Active
- 2011-11-03 WO PCT/US2011/059206 patent/WO2012061630A2/en not_active Application Discontinuation
- 2011-11-03 JP JP2013537826A patent/JP2013541590A/ja active Pending
- 2011-11-03 CN CN2011800582863A patent/CN103269702A/zh active Pending
- 2011-11-03 US US13/288,814 patent/US20120115821A1/en not_active Abandoned
- 2011-11-03 BR BR112013011156-9A patent/BR112013011156B1/pt not_active IP Right Cessation
- 2011-11-03 KR KR1020137014213A patent/KR20130100346A/ko not_active Ceased
- 2011-11-03 KR KR1020187020451A patent/KR101962658B1/ko active Active
- 2011-11-03 CN CN201710317282.1A patent/CN107308163A/zh active Pending
2013
- 2013-05-03 ZA ZA2013/03222A patent/ZA201303222B/en unknown
2015
- 2015-10-21 US US14/918,661 patent/US9763930B2/en active Active
2016
- 2016-10-19 JP JP2016205199A patent/JP2017039760A/ja active Pending
2017
- 2017-08-17 US US15/679,495 patent/US9849123B2/en active Active
- 2017-11-15 US US15/813,641 patent/US10350202B2/en active Active
2018
- 2018-03-22 JP JP2018055022A patent/JP6755895B2/ja active Active
2019
- 2019-06-12 US US16/438,956 patent/US20190290639A1/en not_active Abandoned

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dermatol Surg 2008;34:147-151* *
Dermatol Surg 2010;36:694-700* *
Journal of Drugs in Dermatology 2007, Vol. 6, No. 8, 830-832* *
Southern Medical Journal, 2005, Vol. 98, No. 9, pp. 913-919 *

Also Published As

Publication number	Publication date
MX2013005078A (es)	2013-10-03
RU2013126371A (ru)	2014-12-10
EP2635276A4 (en)	2013-12-18
WO2012061630A2 (en)	2012-05-10
CA2816872C (en)	2019-02-12
US20120115821A1 (en)	2012-05-10
KR20130100346A (ko)	2013-09-10
CN107308163A (zh)	2017-11-03
BR112013011156B1 (pt)	2022-05-03
JP2018135342A (ja)	2018-08-30
EP2635276B1 (en)	2017-07-19
JP2013541590A (ja)	2013-11-14
US20180117033A1 (en)	2018-05-03
KR101962658B1 (ko)	2019-07-31
JP6755895B2 (ja)	2020-09-16
US10350202B2 (en)	2019-07-16
US20160038478A1 (en)	2016-02-11
US20190290639A1 (en)	2019-09-26
US9849123B2 (en)	2017-12-26
WO2012061630A3 (en)	2012-06-28
RU2578979C2 (ru)	2016-03-27
AU2011323271B2 (en)	2016-10-27
EP2635276A2 (en)	2013-09-11
US20170340625A1 (en)	2017-11-30
CN103269702A (zh)	2013-08-28
AU2011323271A1 (en)	2013-05-30
CA2816872A1 (en)	2012-05-10
BR112013011156A2 (pt)	2020-09-01
US9763930B2 (en)	2017-09-19
MX339198B (es)	2016-05-16
ZA201303222B (en)	2014-03-26
JP2017039760A (ja)	2017-02-23
NZ610136A (en)	2015-06-26

Publication	Publication Date	Title
EP2655334A4 (en)	2014-12-31	COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
KR20180085062A (ko)	2018-07-25	피부 상태를 치료하기 위한 조성물 및 방법
WO2012054862A9 (en)	2012-08-30	Agents, compositions, and methods for treating pruritis and related skin conditions
SG2014010706A (en)	2014-05-29	Method and composition
GB201016001D0 (en)	2010-11-10	Composition and method
WO2011137427A9 (en)	2012-04-12	Compositions and methods for treating pulmonary conditions
GB201003531D0 (en)	2010-04-21	Composition and method
EP2659932A4 (en)	2017-05-03	Treatment device and method for operating same
GB2509033B (en)	2019-01-16	Composition for coloring skin and method for coloring skin
GB201008843D0 (en)	2010-07-14	Method and composition
GB201008364D0 (en)	2010-07-07	Composition and method
EP2512504A4 (en)	2013-06-19	COMPOSITION AND THERAPEUTIC METHOD
WO2012057895A9 (en)	2013-03-07	Composition and method for treating wounds
WO2013003465A9 (en)	2013-03-28	Methods and compositions for treating skin
HK1255654A (en)	2019-08-23	Compositions and methods for treating myelofibrosis
AU2010902965A0 (en)	2010-07-22	Antipsoratic composition and method of treatment
AU2010901445A0 (en)	2010-04-22	Composition and method of treatment
EP2528579B8 (en)	2015-11-25	Composition and method for hair removal
AU2011903962A0 (en)	2011-10-13	Water treatment composition and method
AU2010903933A0 (en)	2010-09-16	Method of treatment and agents useful for same
AU2012902645A0 (en)	2012-07-12	Pearl Treatment Composition and Method
HK1179870A (en)	2013-10-11	Method for treating schizophrenia and related diseases
AU2011900991A0 (en)	2011-03-31	Agent and method for treating of pain and other conditions
IL203626A0 (en)	2010-11-30	Composition for treating psoriasis, method for preparation thereof and method for treating psoriasis thereby
AU2010901721A0 (en)	2010-05-13	Method and composition

Legal Events

Date	Code	Title	Description
2018-07-16	A107	Divisional application of patent
2018-07-16	PA0104	Divisional application for international application	Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20180716 Application number text: 1020137014213 Filing date: 20130603
2018-07-18	A201	Request for examination
2018-07-18	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20180718 Comment text: Request for Examination of Application
2018-07-25	PG1501	Laying open of application
2018-09-17	E902	Notification of reason for refusal
2018-09-17	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20180917 Patent event code: PE09021S01D
2018-12-28	E701	Decision to grant or registration of patent right
2018-12-28	PE0701	Decision of registration	Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20181228
2019-03-21	GRNT	Written decision to grant
2019-03-21	PR0701	Registration of establishment	Comment text: Registration of Establishment Patent event date: 20190321 Patent event code: PR07011E01D
2019-03-21	PR1002	Payment of registration fee	Payment date: 20190322 End annual number: 3 Start annual number: 1
2019-07-31	PG1601	Publication of registration
2022-03-04	PR1001	Payment of annual fee	Payment date: 20220307 Start annual number: 4 End annual number: 4
2023-03-06	PR1001	Payment of annual fee	Payment date: 20230307 Start annual number: 5 End annual number: 5